Pemetrexed

Generic Name
Pemetrexed
Brand Names
Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
Drug Type
Small Molecule
Chemical Formula
C20H21N5O6
CAS Number
137281-23-3
Unique Ingredient Identifier
04Q9AIZ7NO
Background

Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...

Indication

Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions
Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
Associated Therapies
Monotherapy
Clinical Trials
Related News

Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Phase 2
Completed
Conditions
Malignant Pleural Mesothelioma
First Posted Date
2006-10-12
Last Posted Date
2007-04-11
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
20
Registration Number
NCT00386815
Locations
🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer

Phase 2
Terminated
Conditions
Non-Small-Cell Lung Cancer
Interventions
Drug: Pemetrexed
Drug: Gemcitabine
First Posted Date
2006-10-03
Last Posted Date
2009-06-03
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
19
Registration Number
NCT00383331
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, Minnesota, United States

A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer

Phase 2
Terminated
Conditions
Esophageal Neoplasms
Interventions
Drug: Pemetrexed
Drug: Carboplatin
First Posted Date
2006-10-03
Last Posted Date
2016-01-11
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
9
Registration Number
NCT00383266
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

Chemotherapy for Patients With Non-Small Cell Lung Cancer

Phase 4
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: pemetrexed
First Posted Date
2006-09-26
Last Posted Date
2010-11-16
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
33
Registration Number
NCT00380718
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan

A Trial for Patients With Advanced/Recurrent Endometrial Cancer

First Posted Date
2006-09-18
Last Posted Date
2009-11-20
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
27
Registration Number
NCT00377520
Locations
🇺🇸

Gynecologic Oncology Group 215-854-0770, Philadelphia, Pennsylvania, United States

Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)

Phase 1
Completed
Conditions
Urologic Neoplasms
Interventions
Drug: pemetrexed
Drug: cisplatin
First Posted Date
2006-09-12
Last Posted Date
2010-11-04
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
59
Registration Number
NCT00374868
Locations
🇪🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santander, Spain

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

Phase 2
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Pemetrexed
Drug: AZD6244
First Posted Date
2006-09-07
Last Posted Date
2014-08-13
Lead Sponsor
AstraZeneca
Target Recruit Count
88
Registration Number
NCT00372788
Locations
🇷🇴

Research Site, Cluj-Napoca, Romania

Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome

Phase 1
Terminated
Conditions
Lymphoma
Interventions
Drug: Gemcitabine
Drug: Pemetrexed
First Posted Date
2006-08-29
Last Posted Date
2019-08-28
Lead Sponsor
Northwestern University
Target Recruit Count
14
Registration Number
NCT00369629
Locations
🇺🇸

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer

First Posted Date
2006-08-15
Last Posted Date
2009-10-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
908
Registration Number
NCT00363415
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor

First Posted Date
2006-07-26
Last Posted Date
2010-08-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
41
Registration Number
NCT00356525
Locations
🇮🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy